drugset
drugset / Trial / NCT04686643

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

NCT04686643 ↗

Phase 3 Unknown 306 enrolled Ahn-Gook Pharmaceuticals Co.,Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

A phase 3 study to evaluate efficacy and safety of AGSAVI

Timeline

Start
2021-02-01
Primary completion
2022-02-01
Completion
2022-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Indapamide Small molecule — —
Background S-amlodipine Unknown — —
Background Valsartan Small molecule — —

Indications

hypertensive disorder